Clinical Trial Search

Primary: Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI — -4.6; -15.1; -9.4 mm^3/year

Primary: Chest Tube Output — 1022; 937 mL — p=0.84

Primary: Generalized Anxiety Disorder-7 at Post-Assessment — 12.5; 12.0; 4.6; 9.1 score on a scale — p=0.035

Primary: Estimated Blood Loss (EBL) — 900; 800 ml — p=0.34

Primary: Observed Response Rate — 0; 11 percentage of patients responding

Primary: Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) — 401; 408; 71; 87 Participants

Primary: Number of Participants Who Experienced the Occurrence of a Third Episode of Post-RSV Wheezing (Recurrent Wheeze) — 45; 33 Participants — p=0.08

Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants

Primary: Treatment Success as Defined as the Composite of Procedural Technical Success, Absence of Vascular Complications, and Absence of Major Adverse Events as Determined by…

Primary: Number of Subjects That Are Lice-free After 2 Treatments With Test Product (Including All Baseline Infestations). — 30; 30 Participants — p=0.023

Primary: Changes in Severity of Functional Dyspepsia Symptoms — 10.1; 10.0; 5.1; 5.2 score on a scale — p=0.041

Primary: Change From Baseline to 4 Weeks (Day 28) in Symptom Assessment in Dry Eye (SANDE) Questionnaire Score — 73.0; 72.7; 56.6; 57.2 Score on a scale — p=0.739

Primary: Efficacy of MS1819-SD: Coefficient of Fat Absorption (CFA) — 55.6; 86.2 % CFA

Primary: Levodopa Cmax Following First Dose on Day 1 — 2857.56; 2173.30 ng/mL

Primary: Improvement on the MCS in All Randomized Participants — 12; 14 Participants — p=0.798